First-line treatment of gastroesophageal adenocarcinoma HER2 targeting bispecific antibody achieves 90.9% disease control rate

Today, Zymeworks announced that it is investigating zanidatamab, a bispecific antibody therapy targeting HER2, and has achieved positive results in a first-line clinical trial for the treatment of HER2-expressing gastroesophageal adenocarcinoma (GEA) patients
.
As of March 18, 2021, of the 22 patients that can be evaluated, zanidatamab was used in combination with standard chemotherapy to achieve a confirmed objective response rate of 68.

Zanidatamab is a bispecific antibody that can simultaneously bind to two non-overlapping epitopes of HER2
.
This unique design produces multiple mechanisms of action, including dual HER2 signal blockade, increased clearance of HER2 protein from the cell surface, and enhanced antibody-mediated cytotoxicity, resulting in encouraging anti-tumor activity in patients

▲Zanidatamab has a unique mechanism of action (picture source: reference [2])

Reference materials:

[1] Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress.

[2] Zymeworks Corporate Presentation.

(The original text has been deleted)